May 29, 2026
.webp "Biocatalysis in Pharmaceutical Manufacturing Process")
Biocatalysis is increasingly shaping how modern pharmaceuticals are developed and manufactured. By using enzymes or whole cells as catalysts, this approach enables highly selective chemical transformations under mild, environmentally friendly conditions. For drug developers, biocatalysis in pharmaceutical manufacturing is becoming a key enabler of faster, cleaner, and more scalable synthesis routes.
As active pharmaceutical ingredients (APIs) become more structurally complex, traditional synthetic methods are often pushed to their limits. While chemocatalysis using metal-based systems remains important, enzyme catalysis offers distinct advantages that make it an attractive complement, or even alternative, to conventional chemistry.
One of the biggest advantages of enzyme-driven synthesis is selectivity. Enzymes provide high chemoselectivity, regioselectivity, and stereoselectivity, reducing the need for protecting groups and simplifying downstream purification.
Biocatalytic reactions typically occur at ambient temperature and pressure, which helps lower energy requirements and reduces the need for specialized equipment. Water is often used as a solvent, supporting green chemistry principles by minimizing hazardous waste and by-products.
Another key benefit is flexibility. Enzymes enable asymmetric synthesis without complex chiral auxiliaries and support late-stage functionalization of sensitive molecules. This makes them especially valuable in modern API development.
Advances in technologies like genome mining, directed evolution, and computational protein design have significantly expanded the capabilities of biocatalysis, improving enzyme stability, substrate scope, and solvent tolerance.
Historically, biocatalysis was used in limited applications, such as brewing or niche transformations. Today, it has evolved into a mainstream tool for both discovery and manufacturing.
Modern biocatalytic reaction toolkits include commercial enzyme panels like lipases, ketoreductases, and transaminases. These allow rapid route scouting without extensive enzyme engineering. In parallel, metagenomic libraries, in silico enzyme design, and biosynthetic pathway repurposing are expanding access to new catalytic functions.
Biocatalysis is also no longer limited to single-step reactions. Multienzyme cascades now enable streamlined synthetic routes with fewer steps, improved atom economy, and tighter stereochemical control.
Different operational formats allow teams to tailor biocatalysis to process needs:
Together, these formats support a broad biocatalytic reaction toolbox spanning oxidation, reduction, amination, hydrolysis, and carbon–carbon bond formation.
Biocatalysis is already reshaping API synthesis routes in industry. It has enabled highly efficient production of chiral alcohols and amines, often achieving >99% enantiomeric excess while eliminating the need for metal catalysts and chiral auxiliaries.
In some cases, enzymatic steps have reduced process complexity by eliminating protecting-group chemistry, improving stereocontrol, and reducing waste. Industrial examples include large-scale production processes, such as acrylamide synthesis using nitrile hydratases.
Chemoenzymatic approaches demonstrate that biocatalytic process intensification can reduce the number of steps and improve manufacturing robustness.
Piramal Pharma Solutions has integrated biocatalysis services across discovery and development, enabling rapid, scalable solutions for complex synthesis challenges. Using off-the-shelf enzymes, teams can quickly evaluate reaction feasibility and optimize routes without lengthy engineering cycles.
At the discovery scale, reactions are performed using controlled lab systems, while development sites support scale-up in jacketed reactors with in-line monitoring. This enables a seamless transition from small-scale screening to larger production volumes.
Case studies demonstrate the versatility of the platform, including stereoselective transformations achieving >98% enantiomeric excess, green chemistry-enabled carbon–carbon bond formation under mild conditions, and stereodivergent synthesis from a single starting material.
Despite rapid progress, biocatalytic process development still faces challenges, including limited substrate scope, enzyme stability under harsh conditions, cofactor efficiency, and compatibility in multienzyme cascades.
However, these challenges are being addressed through directed evolution, computational protein engineering, hybrid chemoenzymatic strategies, and continuous manufacturing technologies.
As these innovations mature, biocatalysis in drug manufacturing is expected to play an even greater role in improving sustainability, reducing costs, and accelerating time-to-market.
Biocatalysis uses enzymes or whole cells to perform chemical reactions in drug development, enabling more selective and environmentally friendly synthesis routes.
Biocatalysis is important for API production because it improves efficiency by reducing reaction steps, increasing selectivity, reducing waste, and enabling milder reaction conditions than traditional chemical methods.
Yes, biocatalytic processes can be scaled from lab to industrial production using immobilized enzymes, whole-cell systems, and controlled reactor technologies.
The following Piramal facility supports biocatalytic processes:
